ATE298236T1 - Bestimmte glycin-derivate als faktor xa inhibitoren zur verwendung in der behandlung von thrombose - Google Patents

Bestimmte glycin-derivate als faktor xa inhibitoren zur verwendung in der behandlung von thrombose

Info

Publication number
ATE298236T1
ATE298236T1 AT02791222T AT02791222T ATE298236T1 AT E298236 T1 ATE298236 T1 AT E298236T1 AT 02791222 T AT02791222 T AT 02791222T AT 02791222 T AT02791222 T AT 02791222T AT E298236 T1 ATE298236 T1 AT E298236T1
Authority
AT
Austria
Prior art keywords
factor
treatment
inhibitors
thrombosis
sup
Prior art date
Application number
AT02791222T
Other languages
English (en)
Inventor
Michael Robert Wiley
Daniel Jon Sall
Christopher William Murray
Stephen Clinton Young
Jolie Anne Bastian
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE298236T1 publication Critical patent/ATE298236T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT02791222T 2001-12-12 2002-12-09 Bestimmte glycin-derivate als faktor xa inhibitoren zur verwendung in der behandlung von thrombose ATE298236T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33932601P 2001-12-12 2001-12-12
PCT/US2002/036150 WO2003049735A1 (en) 2001-12-12 2002-12-09 Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders

Publications (1)

Publication Number Publication Date
ATE298236T1 true ATE298236T1 (de) 2005-07-15

Family

ID=23328487

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02791222T ATE298236T1 (de) 2001-12-12 2002-12-09 Bestimmte glycin-derivate als faktor xa inhibitoren zur verwendung in der behandlung von thrombose

Country Status (7)

Country Link
US (2) US7078415B2 (de)
EP (1) EP1455787B1 (de)
AT (1) ATE298236T1 (de)
AU (1) AU2002366563A1 (de)
DE (1) DE60204800T2 (de)
ES (1) ES2242086T3 (de)
WO (1) WO2003049735A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169795B2 (en) 2003-09-30 2007-01-30 Bristol Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011658A1 (en) 1997-08-29 1999-03-11 Proteus Molecular Design Ltd. Meta-benzamidine derivatives as serin protease inhibitors
US6545055B1 (en) 1999-05-24 2003-04-08 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
CA2375920A1 (en) * 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
US6521609B1 (en) * 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
GB0030305D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030304D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US7265121B2 (en) * 2001-07-26 2007-09-04 Eli Lilly And Company Chemical compounds
EP1456198A1 (de) * 2001-12-12 2004-09-15 Eli Lilly And Company Alanyl-piperidine heterocyclische derivate verwendbar gegen kardiovaskulären erkrankungen

Also Published As

Publication number Publication date
WO2003049735A1 (en) 2003-06-19
US7078415B2 (en) 2006-07-18
ES2242086T3 (es) 2005-11-01
US20070072869A1 (en) 2007-03-29
DE60204800D1 (de) 2005-07-28
US20040249155A1 (en) 2004-12-09
DE60204800T2 (de) 2006-05-04
AU2002366563A1 (en) 2003-06-23
EP1455787A1 (de) 2004-09-15
US7297706B2 (en) 2007-11-20
EP1455787B1 (de) 2005-06-22

Similar Documents

Publication Publication Date Title
CY1105386T1 (el) Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
DE60127863D1 (de) Phenylderivate
DE60324544D1 (de) Muskarin antagonisten
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
ATE469892T1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
CY1115124T1 (el) Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης
ATE311363T1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
DE69928655D1 (de) Substituierte porphyrine
MX2007003470A (es) Compuestos de carbonilo los cuales pueden utilizarse como inhibidores del factor de coagulacion xa.
EA200301100A1 (ru) Новые фталазиноны
DE60221505D1 (de) FAKTOR Xa BENZAMIDIN INHIBITOREN
MY141011A (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
MXPA03007413A (es) Composicion y metodo para tratar enfermedades inflamatorias.
ATE386525T1 (de) 3-substituierte 6,7- dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60202669D1 (de) 6-phenylbenzonaphthyidine
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
MXPA04004307A (es) Derivados de fenoxi-n-`4-(1,1-dioxoisotiazolidin-2-il)fenil-valeramida y otros compuestos como inhibidores del factor de coagulacion xa para el tratamiento de enfermedades tromboembolicas y tumores.
DE60224805D1 (de) 1-glycinyl-4-(1-methylpiperidin-4-yl)piperazine un
DE60204800D1 (de) Bestimmte glycin-derivate als faktor xa inhibitoren zur verwendung in der behandlung von thrombose
CY1105345T1 (el) Φαινυλαλκινια

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties